Ovary Disease Clinical Trial
Official title:
The Relationship Between Oxidative Stress and Apoptosis of Histopathological Changes Made by Mad Honey Containing Grayanotoxin in the Ovary
For our working group, eighteen healthy Sprague-Dawley female rats were recruited and separated into three groups in an experimental animal laboratory. Group 1 was given mad honey (n:6) (80 mg/kg); Group 2 was given normal honey (n:6) (80 mg/kg), and Group 3 was the control group (n:6). The groups were given normal and mad honey by oral gavage for 30 days in this study. Rats were anesthetized intramuscularly with 50 mg/kg ketamine and 5 mg/kg xylazine on the 30th day of the study. At the conclusion of the study, female rats in the proestrus phase of the estrous cycle (as indicated by vaginal smear) were sacrificed and their ovarian tissues were placed in neutral formalin solution.
Status | Recruiting |
Enrollment | 18 |
Est. completion date | December 31, 2022 |
Est. primary completion date | December 15, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 8 Weeks to 10 Weeks |
Eligibility | Inclusion Criteria: - healthy rats Exclusion Criteria: - patient rats - not eating rats |
Country | Name | City | State |
---|---|---|---|
Turkey | Hayrunnisa | Yunusemre | Mani?sa |
Lead Sponsor | Collaborator |
---|---|
Celal Bayar University |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of the Mad Honey and Normal Honey findings of the ovary tissue specimens | Analyses of the relationship between oxidative stress and apoptosis of histopathological changes made by mad honey containing grayanotoxin in the ovary | Baseline |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05001282 -
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRĪ±)
|
Phase 1/Phase 2 | |
Completed |
NCT03897400 -
Ovarian Reserve in Crohn's Disease
|
||
Active, not recruiting |
NCT04817449 -
Spectroscopy in Ovarian Cancer
|